The newly acquired ELITech Molecular Diagnostics business also contributed, positioning Bruker as an emerging infectious disease specialist in the in-vitro diagnostics (IVD) market. Within Bruker’s ...

M&T Bank Corp lifted its stake in Bruker Co. (NASDAQ:BRKR – Free Report) by 303.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 17,870 shares of the medical ...

Bank of New York Mellon Corp increased its stake in Bruker Co. (NASDAQ:BRKR – Free Report) by 7.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Bruker Biospin at $905.70 million, and Bruker Energy & Supercon Technologies (BEST) at $283 million. Estimated Discount To Fair Value: 17.3% Bruker is trading at US$52.92, below its estimated fair ...

Bruker Biospin at $905.70 million, and Bruker Energy & Supercon Technologies (BEST) at $283 million. Bruker Corporation, with substantial insider buying recently, is positioned for significant ...

Bruker BioSpin is the pioneer in the development of CryoProbe technology for high-resolution NMR with over 1,300 CryoProbes installed at customer sites worldwide during the last 14 years.

Bruker ended the fourth quarter of 2024 with both earnings and revenue beating estimates. BioSpin continued to witness saw strong revenue growth in Europe and the Americas, as well as in ...

Bruker (BRKR) reported $979.6 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 14.6%. EPS of $0.76 for the same period compares to $0.70 a year ago.

(3) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID and Nano Segments as presented in our Annual Report on Form 10-K for the year ended December 31 ...